Should You Buy Terns Pharmaceuticals Inc (TERN) Stock on Wednesday?

Overall market sentiment has been down on Terns Pharmaceuticals Inc (TERN) stock lately. TERN receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.

Terns Pharmaceuticals Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on TERN!

See Full TERN Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With TERN Stock Today?

Terns Pharmaceuticals Inc (TERN) stock is trading at $5.65 as of 11:10 AM on Wednesday, Sep 28, a gain of $0.73, or 14.84% from the previous closing price of $4.92. The stock has traded between $5.20 and $5.98 so far today. Volume today is low. So far 57,198 shares have traded compared to average volume of 251,303 shares. To see InvestorsObserver's Sentiment Score for Terns Pharmaceuticals Inc click here.

More About Terns Pharmaceuticals Inc

Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. Click Here to get the full Stock Report for Terns Pharmaceuticals Inc stock.